Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TGF-β blocking antibody
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
TGF-β blocking antibodies are monoclonal antibodies designed to bind and neutralize transforming growth factor-beta (TGF-β) ligands (such as TGF-β1, TGF-β2, and/or TGF-β3). TGF-β is a multifunctional cytokine that plays a critical role in regulating cell growth, differentiation, immune responses, and tissue remodeling. In pathological states, dysregulated TGF-β signaling is implicated in tissue fibrosis, tumor immune evasion, and bone remodeling disorders. In bone biology, TGF-β signaling regulates the quiescence and reactivation of osteoblasts; blocking TGF-β has been shown to stimulate the transition of quiescent bone lining cells into active, bone-forming osteoblasts. Consequently, TGF-β blocking antibodies are being investigated, often in combination with anabolic agents like anti-sclerostin antibodies, as potential therapeutic strategies to enhance bone mass and treat severe osteoporosis.
- Other names
- anti-TGF-beta antibodyanti-TGF-β antibodyTGF-beta blocking antibodyTGF-beta neutralizing antibodyTGF-β neutralizing antibody
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)
Beyond the preview
Go deeper on TGF-β blocking antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGF-β blocking antibody.